40 participants with Eosinophilic Gastritis 12-70 years of age will be randomly assigned with
dupilumab or placebo subcutaneous injections every two weeks for a total of 12 weeks. Study
subjects who complete the 12-week treatment phase, may continue into an open label extension
study, where dupilumab will be administered every two weeks for a total of 24 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborators:
National Institutes of Health (NIH) Regeneron Pharmaceuticals